DarioHealth Corp

NASDAQ DRIO

Data sourced from

and

Daily

Download Data

DarioHealth Corp Price to Sales Ratio (P/S) on June 03, 2024: 2.31

DarioHealth Corp Price to Sales Ratio (P/S) is 2.31 on June 03, 2024, a -46.30% change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

DarioHealth Corp 52-week high Price to Sales Ratio (P/S) is 4.48 on June 13, 2023, which is 93.84% above the current Price to Sales Ratio (P/S).
DarioHealth Corp 52-week low Price to Sales Ratio (P/S) is 1.22 on November 22, 2023, which is -47.01% below the current Price to Sales Ratio (P/S).
DarioHealth Corp average Price to Sales Ratio (P/S) for the last 52 weeks is 2.70.

NASDAQ: DRIO

DarioHealth Corp

CEO	Mr. Erez Raphael
IPO Date	Oct. 6, 2014
Location	United States
Headquarters	18 West 18th Street, New York, NY, United States, 10011
Employees	276
Sector	Healthcare
Industry	Health information services

Description

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Key trends